Pfizer’s Zavicefta shows efficacy against hospital-acquired pneumonia

Pfizer has announced data from a phase III clinical trial showing the effectiveness of its novel combination antibiotic Zavicefta.

Positive results from the REPROVE study showed that Zavicefta offered comparable efficacy in patients diagnosed with hospital-acquired pneumonia treated to Meropenem, the broad-spectrum carbapenem antibiotic that is currently considered the standard of care. 

Similar clinical cure rates at test-of-cure were seen 21 to 25 days after randomisation, meaning Zavicefta met the primary endpoint of the study by helping to resolve all signs and symptoms of infection.

Additionally, patients treated with Zavicefta and Meropenem experienced comparable rates of tolerability consistent with the known profile of the Pfizer drug alone.

These findings demonstrate the benefits of Zavicefta in the treatment of certain Gram-negative infections among patients with limited therapeutic options.

Jill Inverso, vice-president of global medical affairs within Pfizer's critical care medicines unit, said: "The recent introduction of Zavicefta in select European markets, together with planned future global launches, reaffirms our continued commitment to the delivery of new antibiotic therapies that address the needs of patients with serious infections."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.